Carisma Therapeutics Stock Market Value
| CARM Stock | 0.85 0.01 1.19% |
| Symbol | Carisma |
Carisma Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Carisma Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Carisma Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Carisma Therapeutics.
| 01/12/2023 |
| 12/02/2024 |
If you would invest 0.00 in Carisma Therapeutics on January 12, 2023 and sell it all today you would earn a total of 0.00 from holding Carisma Therapeutics or generate 0.0% return on investment in Carisma Therapeutics over 690 days. Carisma Therapeutics is related to or competes with Cns Pharmaceuticals, ZyVersa Therapeutics, Immix Biopharma, Hepion Pharmaceuticals, Zura Bio, Altamira Therapeutics, and Enveric Biosciences. Carisma Therapeutics is entity of United States More
Carisma Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Carisma Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Carisma Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 16.3 | |||
| Value At Risk | (6.38) | |||
| Potential Upside | 4.08 |
Carisma Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Carisma Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Carisma Therapeutics' standard deviation. In reality, there are many statistical measures that can use Carisma Therapeutics historical prices to predict the future Carisma Therapeutics' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.56) | |||
| Total Risk Alpha | (0.92) | |||
| Treynor Ratio | (0.44) |
Carisma Therapeutics Backtested Returns
Carisma Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0787, which signifies that the company had a -0.0787% return per unit of risk over the last 3 months. Carisma Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Carisma Therapeutics' Risk Adjusted Performance of (0.11), standard deviation of 2.91, and Mean Deviation of 2.15 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.99, which signifies possible diversification benefits within a given portfolio. Carisma Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Carisma Therapeutics is expected to follow. At this point, Carisma Therapeutics has a negative expected return of -0.22%. Please make sure to confirm Carisma Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Carisma Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.37 |
Below average predictability
Carisma Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Carisma Therapeutics time series from 12th of January 2023 to 23rd of December 2023 and 23rd of December 2023 to 2nd of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Carisma Therapeutics price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Carisma Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | 0.5 | |
| Residual Average | 0.0 | |
| Price Variance | 0.39 |
Carisma Therapeutics lagged returns against current returns
Autocorrelation, which is Carisma Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Carisma Therapeutics' stock expected returns. We can calculate the autocorrelation of Carisma Therapeutics returns to help us make a trade decision. For example, suppose you find that Carisma Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Carisma Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Carisma Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Carisma Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Carisma Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Carisma Therapeutics Lagged Returns
When evaluating Carisma Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Carisma Therapeutics stock have on its future price. Carisma Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Carisma Therapeutics autocorrelation shows the relationship between Carisma Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Carisma Therapeutics.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Carisma Therapeutics Correlation, Carisma Therapeutics Volatility and Carisma Therapeutics Alpha and Beta module to complement your research on Carisma Therapeutics. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Carisma Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.